CISPLATIN, EPIRUBICIN AND VP 16-213 (CEV) AS INDUCTION REGIMEN IN SMALL-CELL LUNG-CANCER (SCLC)

被引：0
作者：
SCAGLIOTTI, GV [1 ]
GOZZELINO, F [1 ]
DAPUZZO, C [1 ]
ALBERA, C [1 ]
BARDESSONO, F [1 ]
PESCETTI, G [1 ]
机构：
[1] UNIV TURIN,SAN LUIGI GONZAGA HOSP,DEPT PULM DIS,I-10124 TURIN,ITALY
来源：
EUROPEAN JOURNAL OF RESPIRATORY DISEASES | 1986年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：A148 / A148
页数：1
相关论文
共 50 条
  • [41] PHASE-II STUDY OF VP-16 AND CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH EXTENSIVE SMALL-CELL LUNG-CANCER (SCLC)
    EVANS, W
    EISENHAUER, E
    HUGHES, P
    SHEPHERD, F
    FELD, R
    AYOUB, J
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04): : B109 - B109
  • [42] CEVE (CTX+EPI+VCR+VP16) POLICHEMOTHERAPY COMBINATION IN SMALL-CELL LUNG-CANCER (SCLC) - A PILOT-STUDY
    LABIANCA, R
    BERETTA, G
    TEDESCHI, M
    FORMENTI, S
    GAMBROSIER, P
    SORESI, E
    BORGHINI, U
    LUPORINI, G
    CLERICI, M
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1986, 69 : A88 - A88
  • [43] Cisplatin-VP16 combination chemotherapy in elderly patients with small cell lung cancer (SCLC).
    Fernández, R
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 117 - 117
  • [44] PHASE-II STUDY INDUCTION CHEMOTHERAPY IN SMALL CELL LUNG-CANCER (CISPLATINUM, CYCLOPHOSFAMIDE, VP-16-213)
    MEINESZ, AF
    POSTMUS, PE
    SLEYFER, DT
    SLUITER, HJ
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1982, 63 : 47 - 47
  • [45] EFFICACY OF CYCLOPHOSPHAMIDE, EPIRUBICIN, AND ETOPOSIDE ALTERNATING WITH CISPLATIN AND ETOPOSIDE IN THE TREATMENT OF PATIENTS WITH SMALL-CELL LUNG-CANCER
    OZYILKAN, O
    KARS, A
    BALTALI, E
    TEKUZMAN, G
    OZYILKAN, E
    FIRAT, D
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 705 - 705
  • [46] VP-16-213 IN COMBINATION CHEMOTHERAPY WITH CHEST IRRADIATION FOR SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL OF THE PIEDMONT ONCOLOGY ASSOCIATION
    JACKSON, DV
    ZEKAN, PJ
    CALDWELL, RD
    SLATKOFF, ML
    HARDING, RW
    CASE, LD
    HOPKINS, JO
    MUSS, HB
    RICHARDS, F
    WHITE, DR
    COOPER, MR
    STUART, JJ
    CAPIZZI, RL
    SPURR, CL
    JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) : 1343 - 1351
  • [47] COMBINED-MODALITY TREATMENT IN SMALL-CELL LUNG-CANCER (SCLC)
    GREGOR, A
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) : 816 - 818
  • [48] IMMUNOHISTOCHEMICAL PHENOTYPE RELATED TO PROGNOSIS IN SMALL-CELL LUNG-CANCER (SCLC)
    MORITTU, L
    SHEPPARD, MN
    BOBROW, LG
    SOUHAMI, RL
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 231 - 231
  • [49] CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN INDUCTION THERAPY FOR SMALL-CELL LUNG-CANCER - DOSE INTENSIFICATION
    JOHNSON, DH
    MANGUM, MD
    GRECO, FA
    CLINICAL RESEARCH, 1987, 35 (01): : A26 - A26
  • [50] ORAL IFOSFAMIDE AND ETOPOSIDE FOR SMALL-CELL LUNG-CANCER (SCLC) PATIENTS
    CERNY, T
    THATCHER, N
    LIND, M
    CARROLL, K
    BULLETIN EUROPEEN DE PHYSIOPATHOLOGIE RESPIRATOIRE-CLINICAL RESPIRATORY PHYSIOLOGY, 1986, 22 : S101 - S101
12345